Anti-infective properties of proton pump inhibitors: perspectives

Rosa, Taciéli Fagundes da; Foletto, Vitória Segabinazzi; Serafin, Marissa Bolson; Bottega, Angelita; Hörner, Rosmari

doi:10.1007/s10123-021-00203-y

Cited by 5 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They have demonstrated antibacterial activity against Gram-positive bacteria ( S. aureus , E. faecalis ) and a number of Gram-negative bacteria ( P. aeruginosa , E. coli , A. baumannii , K. pneumoniae , E. cloacae , U. urealyticum ), as well as M. tuberculosis . Molecules with antimicrobial activity include esomeprazole, lansoprazole, omperazole, and pantoprazole ( Foletto et al, 2021a ; da Rosa et al, 2022 ). It has been proven that PPIs inhibit the activity of fluoroquinolone efflux pumps in S. aureus strains, which increases the activity of, among others, levofloxacin, ciprofloxacin and norfloxacin in staphylococcal infections ( Thangamani et al, 2015 ).…”

Section: Potential Candidates For Repositioning In the Treatment Of B...mentioning

confidence: 99%

See 1 more Smart Citation

Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning

Glajzner,

Bernat,

Jasińska-Stroschein

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Drug repurposing (repositioning) is a dynamically-developing area in the search for effective therapy of infectious diseases. Repositioning existing drugs with a well-known pharmacological and toxicological profile is an attractive method for quickly discovering new therapeutic indications. The off-label use of drugs for infectious diseases requires much less capital and time, and can hasten progress in the development of new antimicrobial drugs, including antibiotics. The use of drug repositioning in searching for new therapeutic options has brought promising results for many viral infectious diseases, such as Ebola, ZIKA, Dengue, and HCV. This review describes the most favorable results for repositioned drugs for the treatment of bacterial infections. It comprises publications from various databases including PubMed and Web of Science published from 2015 to 2023. The following search keywords/strings were used: drug repositioning and/or repurposing and/or antibacterial activity and/or infectious diseases. Treatment options for infections caused by multidrug-resistant bacteria were taken into account, including methicillin-resistant staphylococci, multidrug-resistant Mycobacterium tuberculosis, or carbapenem-resistant bacteria from the Enterobacteriaceae family. It analyses the safety profiles of the included drugs and their synergistic combinations with antibiotics and discusses the potential of antibacterial drugs with antiparasitic, anticancer, antipsychotic effects, and those used in metabolic diseases. Drug repositioning may be an effective response to public health threats related to the spread of multidrug-resistant bacterial strains and the growing antibiotic resistance of microorganisms.

show abstract

Section: Potential Candidates For Repositioning In the Treatment Of B...mentioning

confidence: 99%

“…2 Potential candidates for repositioning in the treatment of bacterial infections (Younis et al, 2017). Anti-inflammatory drugs, antidepressants, antihypertensives, statins, proton pump inhibitors have been recognized as potential candidates in the process of drug repositioning in the treatment of infectious diseases (da Rosa et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning

Glajzner,

Bernat,

Jasińska-Stroschein

2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…For example, non-inflammatory nonsteroidal drugs alter the activity of Gram(+) bacteria and may enhance the antibiotic's effect and modulate immune system activity [84][85][86]. In addition, proton pump inhibitors have additional antimicrobial activities, which are difficult to assess in terms of clinical efficiency [87].…”

Section: Performance Of the Immune Systemmentioning

confidence: 99%

Antibiotics and ECMO in the Adult Population—Persistent Challenges and Practical Guides

2022

View full text Add to dashboard Cite

Extracorporeal membrane oxygenation (ECMO) is an emerging treatment modality associated with a high frequency of antibiotic use. However, several covariables emerge during ECMO implementation, potentially jeopardizing the success of antimicrobial therapy. These variables include but are not limited to: the increased volume of distribution, altered clearance, and adsorption into circuit components, in addition to complex interactions of antibiotics in critical care illness. Furthermore, ECMO complicates the assessment of antibiotic effectiveness as fever, or other signs may not be easily detected, the immunogenicity of the circuit affects procalcitonin levels and other inflammatory markers while disrupting the immune system. We provided a review of pharmacokinetics and pharmacodynamics during ECMO, emphasizing practical application and review of patient-, illness-, and ECMO hardware-related factors.

show abstract

Tackling multi-drug resistant fungi by efflux pump inhibitors

Engle,

Kumar

2024

Biochemical Pharmacology

View full text Add to dashboard Cite

Anti-infective properties of proton pump inhibitors: perspectives

Cited by 5 publications

References 47 publications

Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning

Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning

Antibiotics and ECMO in the Adult Population—Persistent Challenges and Practical Guides

Tackling multi-drug resistant fungi by efflux pump inhibitors

Contact Info

Product

Resources

About